Business
NewAmsterdam Pharma Provides Corporate Update and Reports Second Quarter 2023 Financial Highlights
-- Announced full data from ROSE2 Phase 2 clinical trial evaluating combination of obicetrapib and ezetimibe, which met the primary endpoint with 63.4% median
About this update from Newamsterdam Pharma Company N.v.
[{"type":"text","content":"-- Announced full data from ROSE2 Phase 2 clinical trial evaluating combination of obicetrapib and ezetimibe, which met the primary endpoint with 63.4% median reduction in LDL-C (p","length":202,"tagName":"div"}]